Incyte (INCY) announced positive topline results from its pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for patients with steroid-refractory acute graft-versus-host disease (GVHD).
The study met its primary endpoint, with a 55% overall response rate (ORR) at Day 28. In addition, the best overall response rate (BORR), the number of patients achieving a response at any time point during the study, was 73% percent. The most common treatment-emergent adverse events of any grade were anemia (61%), thrombocytopenia (61%) and . . .
This content is for paid subscribers.
Today’s Highlights June 21, 2018